Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Steven A. Edmundowicz MD, MASGE Associate Editor

Gail Hecht MD Editor-in-Chief

See All Experts

Published in Gastroenterology

Journal Scan / Research · December 22, 2024

Real-World Long-Term Outcomes of Treatment With Risankizumab in Patients With Crohn's Disease

Clinical Gastroenterology and Hepatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Amar Naik MD

Clinical Gastroenterology and Hepatology

Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study

Clin. Gastroenterol. Hepatol. 2024 Dec 01;22(12)2451-2458.e1, M Fumery, B Caron, X Hébuterne, R Altwegg, X Roblin, C Stefanescu, A Meyer, M Nachury, D Laharie, C Le Berre, L Guillo, A Biron, L Caillo, A Buisson, S Nancey, M Uzzan, L Vuitton, C Gilletta, S Geyl, A Blain, J Kirchgesner, P Ah-Soune, N Duveau, M Vidon, V Abitbol, T Paupard, ML Tran-Minh, A Defrance, L Peyrin-Biroulet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Real-World Long-Term Outcomes of Treatment With Risankizumab in Patients With Crohn's Disease

Additional Info

Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study

Further Reading

PNPLA3 rs738409, Age, Diabetes, Sex, and Advanced Fibrosis Jointly Contribute to the Risk of Major Adverse Liver Outcomes in Patients With MASLD

Endoscopic Hemostasis With PuraStat for Colonic Diverticular Bleeding

Assessing the Pathophysiology of Crohn's-Like Disease of the Pouch Using Single-Cell Analysis of Mucosal Cells

Guidelines on the Pharmacological Management of Patients With Moderate to Severe Ulcerative Colitis

Infliximab Plus Azathioprine vs Azathioprine Alone in Patients With Acute Severe Ulcerative Colitis Responsive to IV Steroids

EsoGuard Plus EsoCheck for Non-Endoscopic Detection of Barrett's Esophagus

Pathophysiology, Diagnosis, and Management of Dumping Syndrome

Histological Predictors of Aggressive Recurrence of HCC After Liver Resection

Association Between Alcohol Consumption Levels and the Severity of MASLD

Once-Daily and Twice-Daily Topical Corticosteroids for Treating Patients With Eosinophilic Esophagitis

Outcomes of Using Subcutaneous Infliximab Biosimilar CT-P13 as Maintenance Therapy in Patients With IBD

Recently Updated